行情

CBMG

CBMG

西比曼生物科技集团
NASDAQ

实时行情|Nasdaq Last Sale

18.06
+0.17
+0.95%
已收盘, 16:00 11/12 EST
开盘
17.53
昨收
17.89
最高
18.12
最低
17.01
成交量
10.57万
成交额
--
52周最高
20.63
52周最低
10.98
市值
3.67亿
市盈率(TTM)
-7.4845
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBMG 新闻

  • Benzinga's Top Upgrades, Downgrades For November 12, 2019
  • Benzinga.20小时前
  • SunTrust sees 16% upside in Amgen in premarket analyst action
  • Seeking Alpha - Article.20小时前
  • 10 Biggest Price Target Changes For Tuesday
  • Benzinga.21小时前
  • Baird Downgrades Cellular Biomedicine Gr to Neutral, Lowers Price Target to $19
  • Benzinga.23小时前

更多

所属板块

生物技术和医学研究
+0.45%
制药与医学研究
+0.31%

热门股票

名称
价格
涨跌幅

CBMG 简况

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.
展开

Webull提供Cellular Biomedicine Group Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。